Stryker launches the TPX HD power tool delivering up to 296% more torque and 40% faster performance in challenging small-bone and joint revision procedures. A discounted cash flow valuation pegs fair value at $206, below the current market trading price after shares slipped 14.6% year-to-date.
Stryker introduced the TPX HD small-bone power tool to support complex orthopaedic procedures such as total joint revisions, minimally invasive and oral maxillofacial surgeries. The device targets cases requiring enhanced visibility and precision when cutting metal or bone.
TPX HD delivers up to 296% more torque and 40% faster high-speed performance versus the TPX Micro Drill, leveraging a tapered attachment design for confined spaces and a heat-barrier housing. Customizable control via I.D. Touch software on the CORE™ 2 Console and specialized attachments enhance ergonomics and versatility.
A new discounted cash flow model calculates fair value at $206 per share, suggesting the stock trades above intrinsic worth. Shares have declined 14.6% year-to-date, marking pressure from broader market trends and valuation concerns.
